Dry Powder Inhaler Devices – Medical Devices Pipeline Product Landscape, 2021

Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices – Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Dry Powder Inhaler Devices Pipeline Landscape report provides key information and data related to:

Extensive coverage of the Dry Powder Inhaler Devices under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Dry Powder Inhaler Devices pipeline products.

Review of Recent Developments in the segment / industry

The Dry Powder Inhaler Devices Pipeline Landscape report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Drainage Device sunder development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

The major companies covered in the “Dry Powder Inhaler Devices – Medical Devices Pipeline Product Landscape, 2021” report:

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs

Scope

Extensive coverage of the Dry Powder Inhaler Devices under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to:

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

Identify and understand important and diverse types of Dry Powder Inhaler Devices under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product’s current stage of development, territory and estimated launch date

Companies mentioned

Adamis Pharmaceuticals Corp

Advent Pharmaceuticals Pty Ltd

Aespira Ltd.

AKELA Pharma Inc. (Inactive)

AstraZeneca Plc

Bayer AG

Cambridge Healthcare Innovations Ltd

Circassia Group Plc

Creare LLC

Eli Lilly and Co

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Hovione Technology Ltd

Iconovo AB

Liquidia Technologies Inc

Lupin Pharmaceuticals Inc

MannKind Corp

Monash University

Nektar Therapeutics

Ology Bioservices Inc

OPKO Health Inc

OtiTopic Inc

Pharmaxis Ltd

Quench Medical Inc

Respira Therapeutics Inc

Respirent Pharmaceuticals Co Ltd

Sandoz International GmbH

Sheffield Hallam University

Shin Nippon Biomedical Laboratories Ltd

Spyryx Biosciences Inc

Sun Pharma Advanced Research Company Ltd

United Therapeutics Corp

University of Kansas

University of Sydney

University of Texas Medical Branch at Galveston

Vectura Group Plc

Verona Pharma Plc

Virginia Commonwealth University

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 10

2 Introduction 11

2.1 Dry Powder Inhaler Devices Overview 11

3 Products under Development 12

3.1 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development 12

3.2 Dry Powder Inhaler Devices – Pipeline Products by Territory 13

3.3 Dry Powder Inhaler Devices – Pipeline Products by Regulatory Path 14

3.4 Dry Powder Inhaler Devices – Pipeline Products by Estimated Approval Date 15

3.5 Dry Powder Inhaler Devices – Ongoing Clinical Trials 16

4 Dry Powder Inhaler Devices – Pipeline Products under Development by Companies 17

4.1 Dry Powder Inhaler Devices Companies – Pipeline Products by Stage of Development 17

4.2 Dry Powder Inhaler Devices – Pipeline Products by Stage of Development 19

5 Dry Powder Inhaler Devices Companies and Product Overview 21

5.1 Adamis Pharmaceuticals Corp Company Overview 21

5.1.1 Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 21

5.2 Advent Pharmaceuticals Pty Ltd Company Overview 22

5.2.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

5.3 Aespira Ltd. Company Overview 23

5.3.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23

5.4 AKELA Pharma Inc. (Inactive) Company Overview 24

5.4.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

5.5 AstraZeneca Plc Company Overview 25

5.5.1 AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 25

5.6 Bayer AG Company Overview 26

5.6.1 Bayer AG Pipeline Products & Ongoing Clinical Trials Overview 26

5.7 Cambridge Healthcare Innovations Ltd Company Overview 27

5.7.1 Cambridge Healthcare Innovations Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

5.8 Circassia Group Plc Company Overview 28

5.8.1 Circassia Group Plc Pipeline Products & Ongoing Clinical Trials Overview 28

5.9 Creare LLC Company Overview 29

5.9.1 Creare LLC Pipeline Products & Ongoing Clinical Trials Overview 29

5.10 Eli Lilly and Co Company Overview 30

5.10.1 Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview 30

5.11 GlaxoSmithKline Plc Company Overview 31

5.11.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 31

5.12 Glenmark Pharmaceuticals Ltd Company Overview 32

5.12.1 Glenmark Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview 32

5.13 Hovione Technology Ltd Company Overview 33

5.13.1 Hovione Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.14 Iconovo AB Company Overview 34

5.14.1 Iconovo AB Pipeline Products & Ongoing Clinical Trials Overview 34

5.15 Liquidia Technologies Inc Company Overview 38

5.15.1 Liquidia Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.16 Lupin Pharmaceuticals Inc Company Overview 41

5.16.1 Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.17 MannKind Corp Company Overview 42

5.17.1 MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview 42

5.18 Monash University Company Overview 47

5.18.1 Monash University Pipeline Products & Ongoing Clinical Trials Overview 47

5.19 Nektar Therapeutics Company Overview 48

5.19.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 48

5.20 Ology Bioservices Inc Company Overview 49

5.20.1 Ology Bioservices Inc Pipeline Products & Ongoing Clinical Trials Overview 49

5.21 OPKO Health Inc Company Overview 51

5.21.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 51

5.22 OtiTopic Inc Company Overview 52

5.22.1 OtiTopic Inc Pipeline Products & Ongoing Clinical Trials Overview 52

5.23 Pharmaxis Ltd Company Overview 55

5.23.1 Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

5.24 Quench Medical Inc Company Overview 56

5.24.1 Quench Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 56

5.25 Respira Therapeutics Inc Company Overview 57

5.25.1 Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 57

5.26 Respirent Pharmaceuticals Co Ltd Company Overview 58

5.26.1 Respirent Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

5.27 Sandoz International GmbH Company Overview 60

5.27.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 60

5.28 Sheffield Hallam University Company Overview 62

5.28.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 62

5.29 Shin Nippon Biomedical Laboratories Ltd Company Overview 63

5.29.1 Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

5.30 Spyryx Biosciences Inc Company Overview 66

5.30.1 Spyryx Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 66

5.31 Sun Pharma Advanced Research Company Ltd Company Overview 67

5.31.1 Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview 67

5.32 United Therapeutics Corp Company Overview 68

5.32.1 United Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview 68

5.33 University of Kansas Company Overview 72

5.33.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 72

5.34 University of Sydney Company Overview 73

5.34.1 University of Sydney Pipeline Products & Ongoing Clinical Trials Overview 73

5.35 University of Texas Medical Branch at Galveston Company Overview 74

5.35.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 74

5.36 Vectura Group Plc Company Overview 75

5.36.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 75

5.37 Verona Pharma Plc Company Overview 78

5.37.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 78

5.38 Virginia Commonwealth University Company Overview 79

5.38.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 79

6 Dry Powder Inhaler Devices- Recent Developments 81

6.1 Jun 08, 2021: MannKind at the Lytham Partners Summer 2021 Investor Conference 81

6.2 May 06, 2021: Nektar Therapeutics Reports First Quarter 2021 Financial Results 81

6.3 Apr 28, 2021: Teva Reports First Quarter 2021 Financial Results 82

6.4 Apr 27, 2021: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed 88

6.5 Apr 12, 2021: Orion publishes Interim Report for January–March 2021 on Tuesday 27 April 2021 91

6.6 Apr 06, 2021: GSK announces Dr Anne Beal to join the Board as Non-Executive Director 92

6.7 Mar 29, 2021: Chiesi and Hephai join forces to develop AI educational tool to improve inhaler use 93

6.8 Mar 25, 2021: Decisions taken by Orion Annual General Meeting on 25 March 2021 93

6.9 Mar 22, 2021: Novartis appoints Karen Hale as Chief Legal Officer 95

6.10 Mar 19, 2021: GSK to highlight scientific research in ovarian and endometrial cancer at SGO 2021 Annual Meeting on Women’s Cancer 96

6.11 Mar 10, 2021: MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference 97

6.12 Mar 03, 2021: Change to the Notice of Orion Annual General Meeting 98

6.13 Mar 02, 2021: MannKind to Participate in H.C. Wainwright Global Life Sciences Conference 98

6.14 Mar 01, 2021: Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference 98

6.15 Feb 18, 2021: MannKind to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021 99

6.16 Feb 18, 2021: OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results 99

6.17 Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021 100

6.18 Feb 18, 2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference 100

6.19 Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets 101

6.20 Feb 11, 2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences 101

6.21 Feb 08, 2021: GSK Consumer Health Pakistan appoints Farhan Muhammad Haroon as CEO 101

6.22 Feb 02, 2021: Jim Fitterling elected to 3M board of directors 102

6.23 Jan 26, 2021: Adamis Pharmaceuticals provides update on its us compounding business 102

6.24 Jan 12, 2021: Vectura Group: Trading update 103

6.25 Jan 06, 2021: Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference 104

6.26 Jan 04, 2021: MannKind to Participate in H.C. Wainwright Bioconnect 2021 Conference 105

6.27 Nov 26, 2020: GLAXOSMITHKLINE: EMTN supplementary prospectus 105

6.28 Oct 23, 2020: Orion starts biologic joint venture in China 105

6.29 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality 105

6.30 Jul 10, 2020: Operation Clean Sweep 107

6.31 Jul 09, 2020: Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020 107

7 Appendix 108

7.1 Methodology 108

7.2 About GlobalData 111

7.3 Contact Us 111

List of Tables

Dry Powder Inhaler Devices – Pipeline Products by Stage of Development 12

Dry Powder Inhaler Devices – Pipeline Products by Territory 13

Dry Powder Inhaler Devices – Pipeline Products by Regulatory Path 14

Dry Powder Inhaler Devices – Pipeline Products by Estimated Approval Date 15

Dry Powder Inhaler Devices – Ongoing Clinical Trials 16

Dry Powder Inhaler Devices Companies – Pipeline Products by Stage of Development 17

Dry Powder Inhaler Devices – Pipeline Products by Stage of Development 19

Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 21

APC-4000- Fluticasone DPI – Product Status 21

APC-4000- Fluticasone DPI – Product Description 21

Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

g60 Dry Powder Inhaler – Product Status 22

g60 Dry Powder Inhaler – Product Description 22

Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23

resQhaler – Product Status 23

resQhaler – Product Description 23

AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

Fentanyl TAIFUN Inhaler – Product Status 24

Fentanyl TAIFUN Inhaler – Product Description 24

AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 25

Duaklir Genuair Metered Dose Inhaler – Product Status 25

Duaklir Genuair Metered Dose Inhaler – Product Description 25

Bayer AG Pipeline Products & Ongoing Clinical Trials Overview 26

Ciprofloxacin Dry Powder Inhaler – Product Status 26

Ciprofloxacin Dry Powder Inhaler – Product Description 26

Cambridge Healthcare Innovations Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

aeolus Dry-Powder Inhaler – Product Status 27

aeolus Dry-Powder Inhaler – Product Description 27

Circassia Group Plc Pipeline Products & Ongoing Clinical Trials Overview 28

Tiotropium bromide DPI – Product Status 28

Tiotropium bromide DPI – Product Description 28

Creare LLC Pipeline Products & Ongoing Clinical Trials Overview 29

Intranasal Dry Powder Inhaler – Product Status 29

Intranasal Dry Powder Inhaler – Product Description 29

Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview 30

Nasal Glucagon Delivery System – Product Status 30

Nasal Glucagon Delivery System – Product Description 30

GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 31

Gemini Multi-Dose Combination Inhaler – Product Status 31

Gemini Multi-Dose Combination Inhaler – Product Description 31

Glenmark Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview 32

Tiogiva – Product Status 32

Tiogiva – Product Description 32

Hovione Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

Papillon – Product Status 33

Papillon – Product Description 33

Iconovo AB Pipeline Products & Ongoing Clinical Trials Overview 34

ICOone – Product Status 34

ICOone – Product Description 34

ICOone – Oxytocin – Product Status 35

ICOone – Oxytocin – Product Description 35

ICOpre – Product Status 35

ICOpre – Product Description 36

ICOres – Product Status 36

ICOres – Product Description 36

Multi-Dose Delivery Device – Product Status 37

Multi-Dose Delivery Device – Product Description 37

Liquidia Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38

LIQ861 – Product Status 38

LIQ861 – Product Description 38

Liquidia Technologies Inc – Ongoing Clinical Trials Overview 39

LIQ861 – A Global, Open-label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients 40

Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 41

Tiotropium DPI – Product Status 41

Tiotropium DPI – Product Description 41

MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview 42

AFREZZA – Medtone Inhaler – Product Status 42

AFREZZA – Medtone Inhaler – Product Description 43

Afrezza – Pediatric Use – Product Status 43

Afrezza – Pediatric Use – Product Description 43

Treprostinil Technosphere – Product Status 44

Treprostinil Technosphere – Product Description 44

MannKind Corp – Ongoing Clinical Trials Overview 45

AFREZZA – Medtone Inhaler – A-One: A Randomized Controlled Trial Evaluating One Drop | Premium with Afrezza versus One Drop | Premium Alone 46

AFREZZA – Medtone Inhaler – Improving Post-prandial Blood Glucose Control with Afrezza During Closed-loop Therapy 46

AFREZZA – Medtone Inhaler – Study Comparing Prandial Insulin Aspart Vs. Technosphere Insulin in Patients with Type 1 Diabetes on Multiple Daily Injections: Investigator-initiated a Real-life Pilot Study-STAT Study 46

Monash University Pipeline Products & Ongoing Clinical Trials Overview 47

Aerosol Delivery System – Product Status 47

Aerosol Delivery System – Product Description 47

Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 48

NKTR-061 – Product Status 48

NKTR-061 – Product Description 48

Ology Bioservices Inc Pipeline Products & Ongoing Clinical Trials Overview 49

GelVac Intranasal Powder Vaccine Delivery System – Product Status 49

GelVac Intranasal Powder Vaccine Delivery System – Product Description 49

NanoGENT – Product Status 50

NanoGENT – Product Description 50

OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 51

Inspiromatic – Product Status 51

Inspiromatic – Product Description 51

OtiTopic Inc Pipeline Products & Ongoing Clinical Trials Overview 52

ASPRIHALE – Product Status 52

ASPRIHALE – Product Description 52

OtiTopic Inc – Ongoing Clinical Trials Overview 53

ASPRIHALE – A Phase I, Single-dose, Open-label, Pilot Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Inhalation Powder with Non-enteric-coated Chewable Aspirin in Healthy Adults 54

Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

Orbital Dry Powder Inhaler – Product Status 55

Orbital Dry Powder Inhaler – Product Description 55

Quench Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 56

Dry Powder Inhaler – Product Status 56

Dry Powder Inhaler – Product Description 56

Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 57

RT234 AOS DPI – Product Status 57

RT234 AOS DPI – Product Description 57

Respirent Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

Advair Diskus – Generic Version – Product Status 58

Advair Diskus – Generic Version – Product Description 58

Flovent Diskus – Generic Version – Product Status 59

Flovent Diskus – Generic Version – Product Description 59

Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 60

Solis Multi-Dose Dry Powder Inhaler – Product Status 60

Solis Multi-Dose Dry Powder Inhaler – Product Description 60

Unit-Dose Dry Powder Inhaler – Product Status 61

Unit-Dose Dry Powder Inhaler – Product Description 61

Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 62

Dry Powder Inhaler – Product Status 62

Dry Powder Inhaler – Product Description 62

Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

STS101 Dry Powder Delivery Device – Product Status 63

STS101 Dry Powder Delivery Device – Product Description 63

Shin Nippon Biomedical Laboratories Ltd – Ongoing Clinical Trials Overview 64

STS101 Dry Powder Delivery Device – An Open-label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine 65

Spyryx Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 66

SPX-250 Dry Powder Inhaler – Product Status 66

SPX-250 Dry Powder Inhaler – Product Description 66

Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview 67

SPARC DPI – Product Status 67

SPARC DPI – Product Description 67

United Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview 68

Tyvaso DPI – Product Status 68

Tyvaso DPI – Product Description 68

United Therapeutics Corp – Ongoing Clinical Trials Overview 69

Tyvaso DPI – A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis 70

Tyvaso DPI – An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease 70

Tyvaso DPI – An Open-label Extension Study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease 70

Tyvaso DPI – An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso 71

University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 72

Dry Powder Inhaler – Product Status 72

Dry Powder Inhaler – Product Description 72

University of Sydney Pipeline Products & Ongoing Clinical Trials Overview 73

Dry Powder Inhaler – Product Status 73

Dry Powder Inhaler – Product Description 73

University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 74

Dry Powder Drug Delivery System – Product Status 74

Dry Powder Drug Delivery System – Product Description 74

Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 75

Digitally – Connected LOMI Device – Product Status 75

Digitally – Connected LOMI Device – Product Description 75

MRX006 – Multidose Combined DPI Inhaler – Product Status 76

MRX006 – Multidose Combined DPI Inhaler – Product Description 76

SKP-2075 – Product Status 76

SKP-2075 – Product Description 77

Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 78

RPL554 – Dry Powder Inhaler – Product Status 78

RPL554 – Dry Powder Inhaler – Product Description 78

Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 79

Drug Delivery Device – Cystic Fibrosis – Product Status 79

Drug Delivery Device – Cystic Fibrosis – Product Description 79

Dry Powder Inhaler – Product Status 80

Dry Powder Inhaler – Product Description 80

List of Figures

Dry Powder Inhaler Devices – Pipeline Products by Stage of Development 12

Dry Powder Inhaler Devices – Pipeline Products by Territory 13

Dry Powder Inhaler Devices – Pipeline Products by Regulatory Path 14

Dry Powder Inhaler Devices – Pipeline Products by Estimated Approval Date 15

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports